Scarica l'app Stockscreener
2.96
3.27%
-0.10
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
John Harlow Joins Larimar Therapeutics as President and Chief Operating Officer - BioBuzz
Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO - Investing.com
Larimar Therapeutics names John Harlow president and COO - Investing.com
Form 8K Larimar Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Larimar Therapeutics names John Harlow president and COO By Investing.com - Investing.com South Africa
Larimar Therapeutics Names John Harlow COO - marketscreener.com
Larimar appoints John B. Harlow, Jr. as President and COO - TradingView
Larimar Therapeutics Strengthens Executive Leadership with - GlobeNewswire
Larimar Therapeutics, Inc. Announces Appointment of John Harlow as President and Chief Operating Officer, Effective September 29, 2026 - marketscreener.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Two cell therapies head toward 2026 milestones. One targets type 1 diabetes. - stocktitan.net
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play - TipRanks
Price to earnings forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Larimar (LRMR) Earnings Snapshot: EPS Prints Above Forecast at the Close; Share Move: The Market Price Advances 2.72%Revenue Miss Report - careplusvn.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.30 Signals Continued Clinical ProgressPost-Earnings Drift - dars.gov.et
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
LRMR Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock UptickAnalyst Drop Coverage - dars.gov.et
Larimar Advances FDA Filing as Drug Costs Push Loss Higher - MyChesCo
Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Cycle Outlook - dars.gov.et
Larimar Therapeutics (LRMR) to Announce Earnings on Thursday - marketbeat.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp - The Globe and Mail
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating - Moomoo
LRMR Maintained by Wedbush -- Price Target Lowered to $11.00 - GuruFocus
Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00 - MarketBeat
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics (LRMR) Advances Nomlabofusp Submission Amid Mixed Financial Signals - GuruFocus
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary - TradingView
Larimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver Quantitative
Larimar: Q2 Earnings Snapshot - marketscreener.com
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - Yahoo Finance
Larimar Therapeutics (LRMR) Gains 3.27% as Biotech Stock Approaches Key $4.32 ResistanceDemand Zone - dars.gov.et
LRMR Q1 2026 Earnings: Loss Narrows to -$0.31 Per Share, Beating Estimates by 43.19%Capex Guidance - dars.gov.et
LRMR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Larimar Therapeutics Inc (LRMR) Cash Flow - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - tradingview.com
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
LRMR|Larimar Therapeutics Inc|Price:4.000|Chg%:-0.010 - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
Larimar Therapeutics Files First Module of BLA for Nomlabofusp in Friedreich's Ataxia TreatmentNew Analyst Coverage - dars.gov.et
Larimar Therapeutics Initiates BLA Submission for Nomlabofusp in Friedreich’s AtaxiaProfit Guidance Range - dars.gov.et
Larimar Therapeutics Files Initial BLA Module for Nomlabofusp in Friedreich's AtaxiaPre-Announcement Alert - dars.gov.et
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):